INVESTORS Annual Reports Financials Investor Presentations Shareholder Information Analysts Speak Events Corporate Policies
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
MEDIA Press Releases Downloadables
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers

FEATURED

2018 ▼
2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Lupin launches novel cholesterol-fighter EZEDOC

December 20, 2005

Lupin receives US FDA approval for Cefprozil Tablets

December 9, 2005

Lupin Limited places US $ 100 million Foreign Currency Convertible Bonds

December 7, 2005

Lupin receives USFDA approval for Cephalexin Capsules

December 1, 2005

Lupin Receives Approval For Conducting Phase II Trials For LLL-3348 (Desoris)

November 28, 2005

Lupin has entered into an agreement with GSK Philippines

October 24, 2005

Lupin Q2FY06 Net Profit Soars 158% to Rs. 452 mn

October 19, 2005

Dr. Vijay Kelkar and Mr. R A Shah join Lupin Board

October 19, 2005

Lupin – Ranbaxy Sign TB deal

September 27, 2005

Lupin and Aspen Sign TB Deal

September 26, 2005

DSM Anti-Infectives India And Lupin Enter Into A Strategic Cooperation For Cephalosporins

September 2, 2005

Lupin receives USFDA approval for Cephalexin Oral Suspension

August 18, 2005

Lupin enters into a co-operation agreement with Kyowa for Japanese market

August 8, 2005

Lupin Q1 FY06 Net Profit doubles to Rs. 432 mn

August 2, 2005

Lupin launches Ceftriaxone vials in the US market

July 21, 2005

Lupin's Goa Non Cephalosporin Oral Dosage Facility Inspected By USFDA

July 8, 2005

Lupin FY 05 Net Sales up 4% at Rs. 11,611 mn

May 20, 2005

Lupin Pharmaceuticals, Inc. and Cornerstone BioPharma, Inc.Enter Co-Promotion Agreement for Suprax®

January 27, 2005

Lupin Net Sales up 10% at Rs. 2,796 mn

January 25, 2005